Company news
Arcutis Biotherapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
September 28, 2025
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
September 16, 2025
Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
September 15, 2025
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
September 2, 2025
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
August 5, 2025
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
July 22, 2025
Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
June 25, 2025
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
June 9, 2025
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
June 5, 2025
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
May 28, 2025
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
May 21, 2025
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
May 15, 2025
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
May 6, 2025
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
May 5, 2025
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
April 16, 2025
Arcutis Announces Chief Financial Officer Transition
April 9, 2025
Arcutis and Padagis Agree to Stay Patent Lawsuit
April 1, 2025
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
March 26, 2025
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age
March 17, 2025
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
March 6, 2025
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
February 27, 2025
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
February 26, 2025
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
February 25, 2025
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 24, 2025
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology
February 23, 2025
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference
February 17, 2025
Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"
February 3, 2025
Arcutis to Present at the Guggenheim SMID Cap Biotech Conference
January 26, 2025
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
January 11, 2025
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
December 15, 2024
Arcutis Announces Promotions on Executive Management Team
December 2, 2024
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
November 12, 2024
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
November 5, 2024
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
October 23, 2024
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
October 22, 2024
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
October 17, 2024
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
September 23, 2024
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
September 23, 2024
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
September 18, 2024
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
September 4, 2024
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
August 27, 2024
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 21, 2024
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
July 31, 2024
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
July 28, 2024
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
July 28, 2024
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
July 22, 2024
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
July 21, 2024
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
July 8, 2024
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
July 8, 2024
Calls
The 5 newest of 16 calls. Every call is listed under its year.
- Arcutis Biotherapeutics (NASDAQ:ARQT) Q2 2026 Earnings Call
Aug 5, 2026
Transcript - Arcutis Biotherapeutics (NASDAQ:ARQT) Q1 2026 Earnings Call
May 6, 2026
Transcript - Arcutis Biotherapeutics (NASDAQ:ARQT) Q4 2025 Earnings Call
Feb 25, 2026
Transcript - Arcutis Biotherapeutics (NASDAQ:ARQT) Q3 2025 Earnings Call
Oct 28, 2025
Transcript - Arcutis Biotherapeutics (NASDAQ:ARQT) Q2 2025 Earnings Call
Aug 6, 2025
Transcript
Decks
The 5 newest of 27 decks. Every deck is listed under its year.
- Q2 2026 Earnings Presentation
Earnings · 17 slides · Aug 5, 2026
- Q1 2026 Earnings Presentation
Earnings · 22 slides · May 6, 2026
- Q4 2025 Earnings Presentation
Earnings · 24 slides · Feb 25, 2026
- Q2 2025 Earnings Presentation
Earnings · 23 slides · Aug 6, 2025
- Q1 2025 Earnings Presentation
Earnings · 22 slides · May 6, 2025